RRM2 and prostate carcinoma: For example, gemcitabine targeting RRM2 are validated for the treatment of non-small-cell lung cancer,50 ovarian cancer,51 pancreatic cancer,52 adrenocortical cancer,53 and oral squamous cell carcinoma.54 We speculate that gemcitabine can be used to treat bladder, colon, kidney, liver and prostate cancers.